Previous 10 | Next 10 |
home / stock / cyccp / cyccp news
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2019 Results Conference Call February 26, 2020 04:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Of...
– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib -venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – – Conference Call Scheduled February 26, 2...
BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2019 fina...
The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this Read more ...
BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at the B...
– Anticancer Activity of CYC065 Monotherapy in Patients with MCL1 Amplified Solid Tumors and CYC065-venetoclax combination in AML /MDS and CLL dose escalation studies – BERKELEY HEIGHTS, N.J., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (...
BERKELEY HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announces that the Company will present at Biote...
BERKELEY HEIGHTS, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, today announced study design and preliminary data from t...
– Investigator-Reported Partial Response in Phase 1 Study of CYC065 as Single Agent – – Conference Call Scheduled November 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, ...
BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Wedn...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock Company Name:
CYCCP Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 37.2% to $0.7466 on volume of 94,759,512 shares GameStop Corporation (GME) rose 0.0% to $46.5702 on volume of 64,189,668 shares Trinity Place Holdings Inc. (TPHS) rose 126.9% to $0....